| 1 |
Aliberti S, Reyes LF, Faverio P, et al. Global initiative for meticillin-resistant Staphylococcus aureus pneumonia (GLIMP): An international, observational cohort study [J]. Lancet Infect Dis, 2016, 16(12):1364-1376.
|
| 2 |
Cassini A, Högberg LD, Plachouras D, et al. Attributable deaths and disability-adjusted life-years caused by infections with antibiotic-resistant bacteria in the EU and the European Economic Area in 2015: a population-level modelling analysis [J]. Lancet Infect Dis, 2019, 19(1):56-66.
|
| 3 |
Thwaites GE, Edgeworth JD, Gkrania-Klotsas E, et al. Clinical management of Staphylococcus aureus bacteraemia [J]. Lancet Infect Dis, 2011, 11(3):208-222.
|
| 4 |
Holland TL, Arnold C, Fowler VG. Clinical management of Staphylococcus aureus bacteremia: a review [J]. JAMA, 2014, 312(13):1330-1341.
|
| 5 |
Holland TL, Raad I, Boucher HW, et al. Effect of algorithm-based therapy vs usual care on clinical success and serious adverse events in patients with Staphylococcal bacteremia: A randomized clinical trial [J]. JAMA, 2018, 320(12):1249-1258.
|
| 6 |
Tong SY, Davis JS, Eichenberger E, et al. Staphylococcus aureus infections: epidemiology, pathophysiology, clinical manifestations, and management [J]. Clin Microbiol Rev, 2015, 28(3):603-661.
|
| 7 |
Thomer L, Schneewind O, Missiakas D. Pathogenesis of Staphylococcus aureus bloodstream infections [J]. Annu Rev Pathol, 2016, 11:343-364.
|
| 8 |
Rupp ME, Karnatak R. Intravascular catheter-related bloodstream infections [J]. Infect Dis Clin North Am, 2018, 32(4):765-787.
|
| 9 |
Surewaard BG, Deniset JF, Zemp FJ, et al. Identification and treatment of the Staphylococcus aureus reservoir in vivo [J]. J Exp Med, 2016, 213(7):1141-1151.
|
| 10 |
Minasyan H. Sepsis and septic shock: pathogenesis and treatment perspectives [J]. J Crit Care, 2017, 40:229-242.
|
| 11 |
Kim KS. Mechanisms of microbial traversal of the blood-brain barrier [J]. Nat Rev Microbiol, 2008, 6(8):625-634.
|
| 12 |
Minejima E, Bensman J, She RC, et al. A dysregulated balance of proinflammatory and anti-inflammatory host cytokine response early during therapy predicts persistence and mortality in Staphylococcus aureus bacteremia [J]. Crit Care Med, 2016, 44(4):671-679.
|
| 13 |
Martínez ML, Ferrer R, Torrents E, et al. Impact of source control in patients with severe sepsis and septic shock [J]. Crit Care Med, 2017, 45(1):11-19.
|
| 14 |
Soriano A, Marco F, Martínez JA, et al. Influence of vancomycin minimum inhibitory concentration on the treatment of methicillin-resistant Staphylococcus aureus bacteremia [J]. Clin Infect Dis, 2008, 46(2):193-200.
|
| 15 |
Liao CH, Chen SY, Huang YT, et al. Outcome of patients with meticillin-resistant Staphylococcus aureus bacteraemia at an Emergency Department of a medical centre in Taiwan [J]. Int J Antimicrob Agents, 2008, 32(4):326-332.
|
| 16 |
Chastre J, Blasi F, Masterton RG, et al. European perspective and update on the management of nosocomial pneumonia due to methicillin-resistant Staphylococcus aureus after more than 10 years of experience with linezolid [J]. Clin Microbiol Infect, 2014, 20(S4):19-36.
|
| 17 |
Cahill TJ, Baddour LM, Habib G, et al. Challenges in infective endocarditis [J]. J Am Coll Cardiol, 2017, 69(3):325-344.
|
| 18 |
Seah J, Lye DC, Ng TM, et al. Vancomycin monotherapy vs. combination therapy for the treatment of persistent methicillin-resistant Staphylococcus aureus bacteremia [J]. Virulence, 2013, 15, 4(8):734-739.
|
| 19 |
Holland TL, Baddour LM, Bayer AS, et al. Infective endocarditis [J]. Nat Rev Dis Primers, 2016, 2:16059.
|
| 20 |
Coburn B, Morris AM, Tomlinson G, et al. Does this adult patient with suspected bacteremia require blood cultures? [J]. JAMA, 2012, 308(5):502-511.
|
| 21 |
Kumar A, Roberts D, Wood KE, et al. Duration of hypotension before initiation of effective antimicrobial therapy is the critical determinant of survival in human septic shock [J]. Crit Care Med, 2006, 34(6):1589-1596.
|
| 22 |
Hamdy RF, Hsu AJ, Stockmann C, et al. Epidemiology of methicillin-resistant Staphylococcus aureus bacteremia in children [J]. Pediatrics, 2017, 139(6):e20170183.
|
| 23 |
Mahajan SN, Shah JN, Hachem R, et al. Characteristics and outcomes of methicillin-resistant Staphylococcus aureus bloodstream infections in patients with cancer treated with vancomycin: 9-year experience at a comprehensive cancer center [J]. Oncologist, 2012, 17(10):1329-1336.
|
| 24 |
Gudiol C, Cuervo G, Shaw E, et al. Pharmacotherapeutic options for treating Staphylococcus aureus bacteremia [J]. Expert Opin Pharmacother, 2017, 18(18):1947-1963.
|
| 25 |
Chen SL, Zhu CY, Zhou H, et al. Efficacy and safety of linezolid among patients with methicillin-resistant Staphylococcus aureus bacteremia [J]. Natl Med J China, 2017, 97(14):1084-1088.
|
| 26 |
Jang HC, Kim SH, Kim KH, et al. Salvage treatment for persistent methicillin-resistant Staphylococcus aureus bacteremia: efficacy of linezolid with or without carbapenem [J]. Clin Infect Dis, 2009, 49(3):395-401.
|
| 27 |
Perencevich EN, Malani PN. Treatment algorithms for staphylococcal bacteremia: Improving clinical care and enhancing antimicrobial stewardship [J]. JAMA, 2018, 320(12):1243-1244.
|
| 28 |
Baddour LM, Wilson WR, Bayer AS, et al. Infective endocarditis in adults: diagnosis, antimicrobial therapy, and management of complications: A scientific statement for healthcare professionals from the American Heart Association [J]. Circulation, 2015, 132(15):1435-1486.
|
| 29 |
Tängdén T, Ramos MV, Felton TW, et al. The role of infection models and PK/PD modelling for optimising care of critically ill patients with severe infections [J]. Intensive Care Med, 2017, 43(7):1021-1032.
|